Iovance Biotherapeutics heads into its August 6 earnings print with short sellers largely dug in — covering has stalled, the stock has given back its momentum, and options traders are quietly turning more defensive.
The covering wave that defined the previous week has run out of steam. Short interest slipped just 0.7% over the past week to 25.4% of free float — roughly 100.7 million shares — after falling nearly 16% the week prior when the stock was ripping higher. That earlier cover brought the position down from around 121 million shares in early July, but the pace has clearly slowed. The short score at 75.6 remains in the 6th percentile of the universe, meaning this is still one of the most heavily shorted names around. Borrow availability has tightened slightly to 70%, down from the mid-70s last week, while cost to borrow remains negligible at under 1%. The lending market shows no distress — this is a crowded short that has stabilised, not one under mechanical pressure to cover.
Options positioning adds a layer of caution. The put/call ratio has crept to 0.29, running modestly above its 20-day average of 0.28 at about 1.2 standard deviations elevated — not extreme, but the direction of travel matters. The PCR has drifted higher every session this past week, suggesting incremental demand for downside protection as the earnings date approaches. For context, the 52-week PCR high sits at 0.37, so there is room for the ratio to climb further if sentiment deteriorates. The stock itself is down nearly 3% on the day and flat on the week at $4.99, after gaining 12% over the past month — the post-rally fade is real.
The Street picture is mixed, and the recent analyst data warrants a note of caution on staleness — the consensus of two hold ratings was last updated in mid-May, and the most recent meaningful target changes date to that period. What the record shows: Chardan Capital trimmed its target to $14 from $16 following the prior earnings print in May, while maintaining a Buy. Barclays reiterated Overweight with an $11 target back in February. UBS sits at Neutral with a $4 target — essentially flat to the current price. The spread between the bull targets and UBS's floor tells the whole story: this is a name where conviction ranges enormously. The bear case centres on manufacturing constraints, regulatory execution risk, and the slow commercial ramp of Amtagvi. The bull case is the TIL therapy platform itself, which remains differentiated if the company can scale.
Institutional flow offers one constructive data point. BlackRock added roughly 2.2 million shares in the quarter ending June 30, bringing its stake to 31 million shares — just under 7% of the company. State Street added more aggressively, buying 6.4 million shares in the same period to reach 3.9% of the float. Those are meaningful passive and quasi-active additions at prices well below where some analysts see fair value. On the insider side, recent activity has been immaterial — small award-related sells from the acting CEO and COO in early June at $4.23, all below $30,000 in value. Nothing to read into.
Earnings history carries a clear warning. The last print on May 7 sent shares down 11.5% on the day and nearly 14% over the following five days. That's the pattern to monitor going into August 6 — a stock with 25% of its float short, a 12% one-month run, and a recent track record of double-digit post-earnings drops. Whether the short interest stabilises further, shifts, or accelerates in the days ahead will be the sharpest signal of how positioned traders are heading into that release.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
